A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, active-controlled study evaluates the efficacy and safety of a
weekly dose of albiglutide as compared with sitagliptin. Subjects who are renally impaired
with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately
controlled on their current regimen of diet and exercise or their antidiabetic therapy of
metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic
medications will be recruited into the study.
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Glucagon-Like Peptide 1 rGLP-1 protein Sitagliptin Phosphate